

**GEOVAX LABS, INC.**  
**Condensed Consolidated Statements of Operations Information**  
*(amounts in thousands, except per share data)*

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2023	2022	2023	2022
Grant revenue	\$ -	\$ -	\$ -	\$ 82
Operating expenses:				
Research and development	6,948	2,721	14,487	5,359
General and administrative	1,652	1,249	4,562	3,364
	<u>8,600</u>	<u>3,970</u>	<u>19,049</u>	<u>8,723</u>
Loss from operations	(8,600)	(3,970)	(19,049)	(8,641)
Interest income	191	2	675	4
Net loss	<u>\$ (8,409)</u>	<u>\$ (3,968)</u>	<u>\$ (18,374)</u>	<u>\$ (8,637)</u>
Loss per common share	<u>\$ (0.32)</u>	<u>\$ (0.17)</u>	<u>\$ (0.69)</u>	<u>\$ (0.63)</u>

**Condensed Consolidated Balance Sheet Information**  
*(amounts in thousands, except common share information)*

	Sep. 30, 2023	Dec. 31, 2022
Assets:		
Cash and cash equivalents	\$ 12,687	\$ 27,613
Other current assets	2,113	1,326
Total current assets	<u>14,800</u>	<u>28,939</u>
Property and other assets, net	1,401	2,409
Total assets	<u>\$ 16,201</u>	<u>\$ 31,348</u>
Liabilities and stockholders' equity		
Total liabilities	\$ 7,082	\$ 4,748
Stockholders' equity	9,119	26,600
Total liabilities and stockholders' equity	<u>\$ 16,201</u>	<u>\$ 31,348</u>
Common shares outstanding	26,695,287	26,334,953